CN103702961A - 含有n-烷基的氘代化合物的制备方法 - Google Patents

含有n-烷基的氘代化合物的制备方法 Download PDF

Info

Publication number
CN103702961A
CN103702961A CN201280036588.5A CN201280036588A CN103702961A CN 103702961 A CN103702961 A CN 103702961A CN 201280036588 A CN201280036588 A CN 201280036588A CN 103702961 A CN103702961 A CN 103702961A
Authority
CN
China
Prior art keywords
alkyl
phenyl
chemical bond
alkylene
structural element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036588.5A
Other languages
English (en)
Chinese (zh)
Inventor
J.阿兹罗特
V.德道
W.霍拉
M.贝勒
L.纽伯特
D.米凯利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN103702961A publication Critical patent/CN103702961A/zh
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/46—Ruthenium, rhodium, osmium or iridium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/08—Monoamines containing alkyl groups having a different number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN201280036588.5A 2011-05-23 2012-05-21 含有n-烷基的氘代化合物的制备方法 Pending CN103702961A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305634 2011-05-23
EP11305634.5 2011-05-23
PCT/EP2012/059344 WO2012160015A1 (en) 2011-05-23 2012-05-21 Process for the preparation of deuterated compounds containing n-alkyl groups

Publications (1)

Publication Number Publication Date
CN103702961A true CN103702961A (zh) 2014-04-02

Family

ID=46146876

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036588.5A Pending CN103702961A (zh) 2011-05-23 2012-05-21 含有n-烷基的氘代化合物的制备方法

Country Status (10)

Country Link
US (1) US9340489B2 (enExample)
EP (1) EP2714624B1 (enExample)
JP (1) JP5925301B2 (enExample)
KR (1) KR20140030267A (enExample)
CN (1) CN103702961A (enExample)
CA (1) CA2834920A1 (enExample)
IL (1) IL229037A0 (enExample)
RU (1) RU2013156864A (enExample)
SG (1) SG194625A1 (enExample)
WO (1) WO2012160015A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438435A (zh) * 2014-11-10 2017-12-05 锻造生命科学有限责任公司 抗‑hcmv组合物和方法
CN109748767A (zh) * 2017-11-07 2019-05-14 朱允涛 一种利用微波反应装置制备氘代胺类化合物的方法
CN110545911A (zh) * 2017-04-27 2019-12-06 杜特里亚饮料有限责任公司 用于由d2制备氘代乙醇的方法
CN110545912A (zh) * 2017-04-27 2019-12-06 杜特里亚饮料有限责任公司 用于由d2o制备氘代乙醇的方法
CN113747870A (zh) * 2018-12-21 2021-12-03 泰兰生物科技有限公司 氟利色林的氘化形式和衍生物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39999A (fr) 2014-06-06 2015-12-10 Res Triangle Inst Agonistes du récepteur de l'apeline (apj) et leurs utilisations
EP3386976A1 (en) 2015-12-09 2018-10-17 Research Triangle Institute, International Improved apelin receptor (apj) agonists and uses thereof
AU2017325870B2 (en) 2016-09-16 2021-07-22 Research Traingle Institute Tetrahydroisoquinoline kappa opioid antagonists
RU2764039C2 (ru) 2016-10-12 2022-01-14 Рисерч Трайэнгл Инститьют Гетероциклические агонисты рецептора апелина (apj) и их применение
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10696677B2 (en) 2016-12-21 2020-06-30 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
US11247987B2 (en) 2017-10-06 2022-02-15 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
CA3109809A1 (en) 2018-08-20 2020-02-27 Duke University Methods and compositions for drugs to treat ophthalmic diseases
MX2021002981A (es) 2018-10-05 2021-05-14 Forma Therapeutics Inc Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148843A (zh) * 1994-03-25 1997-04-30 同位素技术有限公司 用氘代方法增强药物效果
CN1906143A (zh) * 2004-01-23 2007-01-31 和光纯药工业株式会社 使用混合催化剂的重氢化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
EP0335918A1 (en) * 1987-08-07 1989-10-11 Mallinckrodt Diagnostica (Holland) B.V. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
US5075337A (en) * 1989-07-26 1991-12-24 G. D. Searle & Co. Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders
DE69105501T2 (de) 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
WO2002066469A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
TW200413274A (en) * 2002-12-27 2004-08-01 Wako Pure Chem Ind Ltd Deuteration or tritiation method
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
JP5454140B2 (ja) * 2007-07-05 2014-03-26 和光純薬工業株式会社 ルテニウム触媒を用いた重水素化方法
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148843A (zh) * 1994-03-25 1997-04-30 同位素技术有限公司 用氘代方法增强药物效果
CN1906143A (zh) * 2004-01-23 2007-01-31 和光纯药工业株式会社 使用混合催化剂的重氢化方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLES P.CASEY ET.AL.: "Hydrogen transfer to carbonyls and imines from a hydroxycyclopentadienyl ruthenium hydride:Evidence for concerted", 《J.AM.CHEM.SOC》 *
E .MANUELA GARRIDO ET.AL: "Fluoxetine and Norfluoxetine revisited:New insights into the electrochemical and spectroscopic properties", 《J.PHYS.CHEM.A》 *
W.J.S.LOCKLEY ET AL: "Rhodium- and ruthenium-catalysed hydrogen isotope exchange", 《J. LABEL COMPD. RADIOPHARM》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107438435A (zh) * 2014-11-10 2017-12-05 锻造生命科学有限责任公司 抗‑hcmv组合物和方法
CN107438435B (zh) * 2014-11-10 2020-12-04 埃弗里斯生物有限责任公司 抗-hcmv组合物和方法
CN110545911A (zh) * 2017-04-27 2019-12-06 杜特里亚饮料有限责任公司 用于由d2制备氘代乙醇的方法
CN110545912A (zh) * 2017-04-27 2019-12-06 杜特里亚饮料有限责任公司 用于由d2o制备氘代乙醇的方法
CN110545912B (zh) * 2017-04-27 2022-10-04 杜特里亚饮料有限责任公司 用于由d2o制备氘代乙醇的方法
CN110545911B (zh) * 2017-04-27 2022-12-27 杜特里亚饮料有限责任公司 用于由d2制备氘代乙醇的方法
CN109748767A (zh) * 2017-11-07 2019-05-14 朱允涛 一种利用微波反应装置制备氘代胺类化合物的方法
CN113747870A (zh) * 2018-12-21 2021-12-03 泰兰生物科技有限公司 氟利色林的氘化形式和衍生物
CN113747870B (zh) * 2018-12-21 2025-08-01 泰兰生物科技有限公司 氟利色林的氘化形式和衍生物

Also Published As

Publication number Publication date
EP2714624A1 (en) 2014-04-09
US20140081019A1 (en) 2014-03-20
CA2834920A1 (en) 2012-11-29
WO2012160015A1 (en) 2012-11-29
JP5925301B2 (ja) 2016-05-25
SG194625A1 (en) 2013-12-30
RU2013156864A (ru) 2015-06-27
JP2014524888A (ja) 2014-09-25
KR20140030267A (ko) 2014-03-11
IL229037A0 (en) 2013-12-31
US9340489B2 (en) 2016-05-17
EP2714624B1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
CN103702961A (zh) 含有n-烷基的氘代化合物的制备方法
US20030105135A1 (en) Phenoxypropanolamines, preparation and therapeutic use thereof
TW200800220A (en) New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
KR20080005997A (ko) 페녹시프로필피페리딘류와 -피롤리딘류 및 이들의 히스타민ｈ3-수용체 리간드로의 용도
EP1870405A1 (en) Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
GB2248449A (en) Diarylalkyl-4-aryl piperazine derivatives
JP2020511515A (ja) ５−ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用
JP2020511506A (ja) シグマ−２受容体の新規調節物質およびその使用方法
TW200918506A (en) Indane-amine derivatives, their preparation and use as medicaments
CN116057042B (zh) 丙烯酰胺取代的茚满化合物及其治疗用途
JP2002535365A (ja) 抗うつ性複素環化合物
US9108990B2 (en) Cyclopropyl MIDA boronate
JP2010517952A (ja) ５−ｈｔ７受容体リガンドとしての複素環置換テトラヒドロナフタレン誘導体
CN1469862A (zh) 2,2-二苯基丁酰胺衍生物和含有它的药物
JP2010513361A (ja) ヘテロシクリル基によって置換されたエチルアミノフェニル誘導体、その調製方法、および医薬としての使用方法
AU2006315684A1 (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN117447385A (zh) 氘代的3-氨甲基-4-苯基哌啶-4-醇类化合物的制备及其用途
CN118221492A (zh) 一种制备(e)-n n-二取代-n′-磺酰基脒的方法
JP2007099640A (ja) 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CN108373469A (zh) 二芳基乙二醚类化合物及其在药学上可接受的水合物或盐、合成方法及其在抗肿瘤上的应用
US9108936B2 (en) Substituted 4-aminobenzamides as KCNQ2/3 modulators
WO2023016249A1 (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法
TW200540142A (en) New β-ketoamide compounds with MCH receptor antagonistic activity and medicaments comprising them
CN107382999A (zh) 含咔唑基噻唑烷酮及其制备方法
JP2022513942A (ja) エストロゲン受容体拮抗剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140402